hotspot -WSS

hotspot

author：entertainment 2025-09-29 16:34:49 - browse：179

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare bonuses could stop drug shortages under Senate plan

focus

WSS

NEJM study measures Covid brain fog, impact on IQ

Dana Farber says 6 studies to be retracted and 31 corrected

Flu vaccine reformulation won't be easy, manufacturers warn

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

CVS is on a mission to consolidate health care. Will it work?

TikTok, Instagram influencers need more rules for drug ads

entertainment

hotspot

focus

Duchenne breakthrough therapy leaves behind pioneering families

5 ways to address the shortage of health care workers

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

In Memoriam: Notable people who died in 2023

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

The high cost of giving birth even with insurance

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

focus

Medicare isn't yet testing food as medicine

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Cardiologists urge adding sexual orientation, gender identity to health records

CDC advisory group OKs chikungunya vaccine

Medicare bonuses could stop drug shortages under Senate plan

Using force crossed my mind when examining a defiant young patient

knowledge

focus

focus

focus